VEMLIDY offers simple dosing for your patients1

No recommended dosing
change for patients with
mild hepatic impairment
(Child-Pugh A)1:

  • VEMLIDY is not recommended in
    patients with decompensated
    (Child-Pugh B or C) hepatic
    impairment

VEMLIDY is a
25-mg pill
that's 8 mm in
diameter.

Taken once-daily
with food

Pill image not to scale.

VEMLIDY is not recommended in patients with ESRD who are not receiving chronic hemodialysis or in patients with decompensated
(Child-Pugh B or C) hepatic impairment.1

VEMLIDY is the only oral antiviral for adults with chronic hepatitis B that doesn’t require a
dose adjustment for renal impairment1-3

Dose adjustment in adult chronic hepatitis B patients with renal impairment

(with preferred first-line oral antiviral therapies)1-3

aVEMLIDY is not recommended in patients with ESRD (eCrCl <15 mL/min) who are not receiving chronic hemodialysis.1

This chart does not include the complete prescribing and dosing considerations for these medications. Please refer to the full Prescribing Information for each medication. Comparison of agents does not imply comparable clinical effectiveness, safety, or tolerability. Individual prescribing decisions should be made at the discretion of the provider.

bGeneric tenofovir disoproxil fumarate and generic entecavir are therapeutically equivalent to the respective brand name drug. These generic drug products are designated Therapeutic Equivalence Code AB, which the FDA considers therapeutically equivalent to other pharmaceutically equivalent products. Please refer to the appropriate manufacturers of generic tenofovir disoproxil fumarate and generic entecavir for the full Prescribing Information.

cAvailable in tablet or powder formulation for tenofovir disoproxil fumarate, or tablet or solution formulation for entecavir. Dosage shown is for adult patients with renal impairment.2,3

VEMLIDY is the only NA that requires no dose adjustments in patients with creatinine clearance
<50 mL/min.1-3

VEMLIDY is the only NA that requires no dose adjustments in patients with creatinine
clearance <50 mL/min.1-3

eCrCl=estimated creatinine clearance; ESRD=end stage renal disease; NA=nucleoside/nucleotide analog.

Dosage and Administration
  • Testing Prior to Initiation: HIV infection.
  • Prior to or When Initiating, and During Treatment: On a clinically appropriate schedule, assess serum creatinine, estimated creatinine clearance, urine glucose, and urine protein in all patients. In patients with chronic kidney disease, also assess serum phosphorus.
  • Dosage in Adults: 1 tablet taken once daily with food.
  • Renal Impairment: Not recommended in patients with end stage renal disease (ESRD; eCrCl <15 mL/min) who are not receiving chronic hemodialysis; in patients on chronic hemodialysis, on hemodialysis days, administer VEMLIDY after completion of hemodialysis treatment.
  • Hepatic Impairment: Not recommended in patients with decompensated (Child-Pugh B or C) hepatic impairment.

Chronic hep B information for your patients

See educational materials

VEMLIDY Co-pay Savings Program

Help your eligible patients save up to $6000 annually

References: 1. VEMLIDY Prescribing Information. Foster City, CA: Gilead Sciences, Inc.; March 2024. 2. TDF (tenofovir disoproxil fumarate) Prescribing Information. Foster City, CA: Gilead Sciences, Inc.; April 2019. 3. BARACLUDE (entecavir) Prescribing Information. Princeton, NJ: Bristol-Myers Squibb; November 2019.